Lanean...

Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations

Imatinib is an inhibitor of the Abl tyrosine kinase domain that is effective in the treatment of chronic myelogenic leukemia (CML). Although imatinib binds tightly to the Abl kinase domain, its affinity for the closely related kinase domain of c-Src is at least 2000-fold lower. Imatinib recognition...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Seeliger, Markus A., Ranjitkar, Pratistha, Kasap, Corynn, Shan, Yibing, Shaw, David E., Shah, Neil P., Kuriyan, John, Maly, Dustin J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2678021/
https://ncbi.nlm.nih.gov/pubmed/19276351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-3953
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!